

MANAGEMENT OF PREGNANCIES

RESULTING FROM

IN-VITRO FERTILIZATION

© Copyright 2022 Society for Maternal-Fetal Medicine in collaboration with Lauren Meiss, MD

in the U.S. Assisted Reproductive Technology accounts for UNCOMPLICATED

in the U.S. Assisted Reproductive Technology accounts for 1.6% of all infants & 18.3% of all multi-birth infants

GENETICS

- Trate of de-novo chromosomal abnormalities reported in ICSI pregnancies compared with the general population
- Other factors that may 1 risk of chromosomal anomalies:
 - · Advanced Maternal Age
 - · polycystic ovary syndrome
 - · severe male & female factor infertility
- Patients with reduced ovarian reserve & primary
 ovarian insufficiency have 1 risk of being full
 mutation or premutation carriers of fragile X
 & typically undergo FMR1 gene testing before IVF

suggest genetic counseling be offered to all patients undergoing or who have undergone IVF */- ICSI

PREIMPLANTATION GENETIC TESTING (PGT)

should be offered for monogenetic disorders with the transfer of only embryos carrying the normal X chromosome

TYPES OF PGT

PGT-A For de novo aneuploidies

Does not replace prenatal screening/diagnosis

PGT-M For monogenetic disorders

For couples with previous offspring affected by single-gene disorders or who have undergone carrier screening with both partners + For a mutation associated with a genetic disease

PGT-SR For siructural [chromosomal] rearrangements

when one partner is a carrier of a balanced translocation

or a deletion or duplication

Regardless of whether PGT has been performed, recommend all patients who have achieved pregnancy with INF be offered prenatal genetic screening a diagnostic testing via CVS or amniocentesis



increased 1 risk of false-positive results for aneuploidies

, confirmatory, pregnancy

recommend offering diagnostic test in 1

- · low fetal fraction
- higher rates of failed cfDNA compared with naturally occurring pregnancies
 - -not a risk factor for failed resuts on 2nd draw

Recommend that the accuracy of first-trimester screening, including cfDNA for ancuploidy, be discussed with patients undergoing or who have undergone IVF

Recommend counseling be offered regarding the option of multifetal pregnancy reduction

multifetal pregnancy reduction has been shown to significantly \blacksquare risks of preterm birth, neonatal morbidity, \bigstar maternal complications

MULTIFETAL PREGNANCY

CONGENITAL ANOMALIES

increased?

 meta-analyses demonstrate associations betw/INF/ICSI & congenital malformations
 unclear if due to infertility, factors associated with the procedure, or both Suc

data unclea

Suggest fetal echo be offered for pregnancies achieved with IVF/ICSI *

Recommend detailed OB ultrasound exam (CPT 76811) for pregnancies achieved with IVF/ICSI

PLACENTAL ANOMALIES

Recommend careful exam of placental location, shape, it cord insertion at time of detailed fetal anatomy, with eval for vasa previa

consider TVUS to rule out vasa previa in all IVF pregnancies with



velamentous cord insertion



resolved placenta previa



Succenturiate or bilobed placenta

* reassess at 32 weeks

- a meta-analysis of singleton pregnancies demonstrated that IVF is associated w/ higher odds of preterm delivery, low birthweight compared w/ naturally occurring pregnancies
- . such risks are more than doubled in IVF twin gestations
- · Subfertility is also a major risk factor for prematurity

Although visualization of the cervix at the anatomy assessment is recommended, we do NOT recommend serial cervical length assessment for IVF pregnancies

PRETERM

Discontinuation of progesterane supplementation initiated for the sole purpose of IVF is recommended

by 12 weeks

FETAL GROWTH RESTRICTION

an increased risk of small for gestational age (SGA) infants is documented in singleton IVF pregnancies

Suggest an assessment of fetal growth in the 3rd trimester for IVF pregnancies

* serial growth US NOT recommended

Recommend low-dose aspirin if IVF pregnancy + one or more additional risk factors for preeclampsia

ASPIRIN

STILLBIRTH

IVF pregnancies have a 2 to 3-fold increased risk of stillbirth even after controlling for maternal age, parity, & multifetal gestations

Suggest weekly antenatal fetal surveillance beginning by 36% weeks of gestation for IVF pregnancies

it is unknown whether elective delivery at 39 weeks reduces the risks of maternal morbidity a improves perinatal outcomes in IVF pregnancies compared with expectant management

Recommend shared decision-making betw/ patients & healthcare providers when considering induction of labor at 39 weeks

